OR WAIT null SECS
July 02, 2021
CMOs and CDMOs adjust business processes as demand for COVID-19 treatments and non-pandemic related therapies puts pressure on the bio/pharma industry.
July 01, 2021
The extended manufacturing agreement between Pinteon and Lonza enables future clinical production of PNT001, a novel Tau antibody therapeutic that targets Alzheimer's disease and traumatic brain injury.
Selexis and KBI Biopharma will use integrated services to advance Immatics’ TCR bispecifics drug development program to the IND stage.
Catalent expands capabilities for stem cell-based therapies with acquisition of RheinCell’s GMP-grade human iPSCs.
Vectura will provide preclinical development services for Incannex’s inhaled drug product for the treatment of traumatic brain injury.
June 30, 2021
CDMO Yposkesi will increase its current gene therapy vector capacity through French government’s “Plan de Relance” scheme.
June 23, 2021
Centrient started production at its new statins API manufacturing unit in Toansa, India.
June 08, 2021
VIVEbiotech has opened its new lentiviral vector manufacturing facilities in Spain, expanding capacity for lentiviral vectors for use in cell and gene therapies.
AGC Biologics has partnered with BioNTech to further supply plasmid DNA starting material from its Heidelberg, Germany, facility for the Pfizer-BioNTech COVID-19 vaccine.
June 04, 2021
MedPharm’s new facility for process development and small-scale manufacturing is in North Carolina, near its existing R&D center.